Cleveland BioLabs (CBLI)
Cleveland BioLabs Revenue Growth: -62.35%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CBLI Revenue Growth Rankings
| Overall | 1st percentile | 4330 of 4381 |
| Sector | 4th percentile | 440 of 460 in Healthcare |
| Industry | 7th percentile | 116 of 126 in Biotechnology |
CBLI Revenue Growth Range, Past 5 Years
| Minimum | -86.49% | Jun 2011 |
| Maximum | 520.6% | Jun 2009 |
| Average | 82.34% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these CBLI related companies
CBLI News
$CBLI filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3aaL
about 24 days ago by MarketBrief
about 24 days ago by MarketBrief
Cleveland BioLabs and Incuron Announce Russian Regulatory Allowance of IND for Phase 1B Trial of CBLC137
Apr 30, 9:00AM GlobeNewswire
Apr 30, 9:00AM GlobeNewswire
Cleveland BioLabs to Report First Quarter Financial Results and Provide Operational Update on May 3
Apr 25, 9:00AM GlobeNewswire
Apr 25, 9:00AM GlobeNewswire
Cleveland BioLabs Provides Update on BARDA Development Funding Process and Meetings With FDA
Apr 03, 6:03PM GlobeNewswire
Apr 03, 6:03PM GlobeNewswire
Cleveland BioLabs (CBLI) Shares Volatile Following New Outperform Rating at Rodman & Renshaw
Mar 14, 3:56PM Street Insider
Mar 14, 3:56PM Street Insider
RT @danshep55 New positions bought friday $NOAH 8 $GMXR 1/2 left 1.97 $CBLI 3.40/thx for the update - good to know what the pros are doing
about 89 days ago by ivan_bg
about 89 days ago by ivan_bg
Cleveland BioLabs Announces Science Publication on Molecular Mechanisms Underlying CBLB502's Interaction With TLR5
Feb 16, 2:00PM GlobeNewswire
Feb 16, 2:00PM GlobeNewswire
Cleveland BioLabs to Present at 14th Annual BIO CEO and Investor Conference
Feb 06, 9:00AM Marketwire
Feb 06, 9:00AM Marketwire
Cleveland Biolabs (CBLI) Fonstein to Step Down as CEO, Will Remain Pres; Kogan Named Interim CEO
Jan 24, 9:07AM Street Insider
Jan 24, 9:07AM Street Insider
Cleveland BioLabs Publishes Manuscript on New Radiation Countermeasure CBLB613
Jan 17, 9:00AM Marketwire
Jan 17, 9:00AM Marketwire
Cleveland BioLabs to Present at Noble Financial Eighth Annual Equity Conference
Jan 11, 9:00AM Marketwire
Jan 11, 9:00AM Marketwire
$CBLI moving on the back of $DNDN SQUEEZE ...to funny...next $CLDX to $5.00 a possibility
about 141 days ago by EXPstocktrader
about 141 days ago by EXPstocktrader
$CBLI http://stks.co/1m7z Updated chart. Alerted at $2.99. Screw you @traderdigs
about 141 days ago by VexTrades
about 141 days ago by VexTrades
Cleveland BioLabs Announces Opening of New IND for CBLB502 in Cancer Patients
Oct 19, 9:02AM Benzinga
Oct 19, 9:02AM Benzinga
Journal of Immunology Publishes Study of Cleveland BioLabs' Drug CBLB502 in Acute Renal Ischemic Failure
Oct 03, 9:00AM Marketwire
Oct 03, 9:00AM Marketwire
Cleveland BioLabs (CBLI) Enters Joint Stock Agreement with RUSNANO for Panacela Labs Funding
Sep 26, 8:02AM Street Insider
Sep 26, 8:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBLI | 1.22 | -0.01 | -0.81% | 43.80M |
| CBL | 17.54 | -0.12 | -0.68% | 2.624B |
| CBKN | 2.20 | +0.02 | +0.92% | 187.04M |
| CBK | 1.39 | -0.03 | -2.11% | 51.12M |
| CBI | 37.65 | -0.31 | -0.82% | 3.710B |
| CBB | 3.43 | -0.05 | -1.44% | 685.56M |
| CBAN | 4.50 | +0.30 | +7.14% | 35.45M |
| CB | 72.06 | +0.40 | +0.56% | 19.38B |
| CAVM | 23.86 | -0.78 | -3.17% | 1.217B |
| CAT | 91.91 | -0.56 | -0.61% | 59.88B |
